Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 22, 2019British Journal of CancerOpen Access

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

View Full Paper
Ask AI
Bookmark
Share

Authors

CSCésar SerranoAMAdrián Mariño‐EnríquezDTDerrick L. Tao

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Serrano et al. (2019) studied this question.

synapsesocial.com/papers/6a7126e2ac440176ef29d593https://doi.org/10.1038/s41416-019-0389-6
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1<i>PDGFRA</i> Activating Mutations in Gastrointestinal Stromal Tumors2003 · 2,308 citations
  2. 2Gain-of-Function Mutations of c- <i>kit</i> in Human Gastrointestinal Stromal Tumors1998 · 4,516 citations
  3. 3Sorafenib Inhibits the Imatinib-Resistant <i>KIT</i> <i>T670I</i> Gatekeeper Mutation in Gastrointestinal Stromal Tumor2007 · 140 citations
  4. 4Dasatinib (BMS-354825), a Dual SRC/ABL Kinase Inhibitor, Inhibits the Kinase Activity of Wild-Type, Juxtamembrane, and Activation Loop Mutant KIT Isoforms Associated with Human Malignancies2006 · 470 citations